Φορτώνει......
Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?
The use of rituximab for the treatment of immune thrombocytopenia was greeted enthusiastically: it led to up to 60% response rates, making it, nearly 20 years ago, the main alternative to splenectomy, with far fewer side effects. However, long-term follow-up data showed that only 20-30% of patients...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Haematologica |
|---|---|
| Κύριοι συγγραφείς: | , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Ferrata Storti Foundation
2019
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6545833/ https://ncbi.nlm.nih.gov/pubmed/31126963 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2019.218883 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|